April 27, 2012

Navidea Biopharmaceuticals First Quarter 2012 Earnings and Business Update Conference Call Invitation

- Conference Call Scheduled for 8:30 AM EDT, Thursday, May 3rd -

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB), specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the first quarter of 2012 on Wednesday, May 2, 2012 after market close. The announcement will be followed by a conference call with the investment community the following day, Thursday, May 3, 2012 at 8:30 am EDT.

Navidea's President and CEO, Dr. Mark Pykett, Executive Vice President and Chief Business Officer, Dr. Thomas Tulip, and CFO, Brent Larson, will provide a development and business update and will discuss the Company's financial results for the first quarter of 2012 during the conference call. The conference call can be accessed as follows:

CONFERENCE CALL INFORMATION			
TO PARTICIPATE LIVE:		**TO LISTEN TO A REPLAY:**	
		Available until:	May 17, 2012
Date:	May 3, 2012	Toll-free (U.S.) Dial in # :	(877) 660-6853
Time:	8:30 am EDT	International Dial in # :	(201) 612-7415
Toll-free (U.S.) Dial in # :	(877) 407-8033	Replay passcode:	
International Dial in # :	(201) 689-8033	Account #:	286
		Conference ID #:	393568

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek®, AZD4694 and RIGScan™ – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals, Inc.

Brent Larson, 614-822-2330
Sr. VP & CFO

Source: Navidea Biopharmaceuticals, Inc.